Bionoid Pharma, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Patricia Colvin
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 433 North Camden Beverly Hills CA United States of America 90210
- IPO Date
- Jun 29, 2007
- Website
- bionoidinc.com
- Similar Companies
- Business
- Bionoid Pharma, Inc. (BINP) is a health and wellness company focused on acquiring revenue-generating e-commerce platforms in the health supplements sector and integrating proprietary artificial intelligence technologies to optimize customer engagement and operational efficiency; its core offerings include the AI Maverick Intel platform, which enables automated customer acquisition, personalized marketing, real-time analytics, and tailored recommendations across healthcare, biotech, and wellness verticals; through its wholly owned subsidiary Enhanced Supplements Ltd., the company provides high-quality supplements targeted at bodybuilding, resistance training, and general health consumers. Founded in 2021 and headquartered in Mississauga, Ontario, Canada, with operational addresses referenced in Beverly Hills, California, United States, Bionoid Pharma conducts business primarily in North America while pursuing global expansion in e-commerce and AI-driven health solutions. Recent strategic developments include the August 2024 acquisition of AI Maverick Intel intellectual property from Stronghold Media Group Corp., accompanied by the divestiture of its Medical Magnetics Inc. stake to streamline focus on AI growth; the November 2024 incorporation and subsequent acquisition of Enhanced Supplements Ltd., an e-commerce platform specializing in wellness products; a December 2024 binding letter of intent to acquire an additional platform from Vitawin Supplements Ltd.; and a January 2025 corporate update outlining 2025 priorities for further e-commerce acquisitions in health and wellness integrated with AI Maverick enhancements.
AI Maverick Intel Provides Corporate Update
IBN Initiates Coverage of AI Maverick Intel Inc.
AI Maverick Launches Enhanced Prospecting Platform to Deliver Human Like Outreach - No SDR Team Required
Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval
Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
Bionoid Pharma Announces Filing of OTCQB Application to Enhance Market Visibility and Liquidity
Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
Bionoid Pharma, Inc. Provides Corporate Update and Outlines Growth Strategy for 2025
Bionoid Pharma, Inc. Reports Over $100,000 in Revenue Following Binding LOI With Your Supplement Supply Store Ltd.
Bionoid Pharma, Inc. Moves to Expand E-Commerce Presence With Binding Agreement to Acquire Platform From Vitawin Supplements Ltd.
AI Maverick: The Next Evolution of Sales Automation Unveiled in Exclusive Podcast
The End of SDRs? AI Maverick Sales Automation, One Touchpoint at a Time
Bionoid Pharma, Inc. Launches Enhanced Supplements Ltd. to Drive Strategic E-Commerce Expansion
Bionoid Pharma, Inc. Signs Binding Letter of Intent to Acquire Main E-Commerce Platform of Your Supplement Supply Store Ltd.
Bionoid Pharma, Inc. Engages Olayinka Oyebola & Co. as PCAOB External Auditor for Annual Financial Audit
Bionoid Pharma, Inc. Unveils Five-Year Strategic Roadmap
Bionoid Pharma Inc. Provides Update on Binding Letter of Intent to Acquire Global Alerts Corp.
Bionoid Pharma Signs Exclusive License Agreement with Global Alerts Corp.